Press Releases

Crucell and Aeras Announce Start of Tuberculosis Vaccine Clinical Trial

October 24, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has started the phase I clinical trial of the AdVacĀ®-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test the vaccine in a dose-escalation trial involving 24 healthy volunteers. The Phase I trial will be funded and managed by Aeras through a Contract Research Organization (CRO), PRA Clinical Pharmacology Center in Lenexa, Kansas, USA. The main parameters under examination will be safety, tolerability and immunogenicity.

Aeras Opens New Vaccine Facility

March 7, 2006 - On March 23rd, the day before World TB Day, the Aeras Global TB Vaccine Foundation will inaugurate a new research and production facility in Rockville, Maryland to help meet the world's need for an advanced tuberculosis vaccine. Using advanced manufacturing technology and capable of producing 150 million vaccine doses per year, the facility ensures rapid scale up of the production of new vaccines.

Partnership Underlines ACE BioSciences’ Unique Protein Identification Capabilities

December 18, 2005 - ACE BioSciences A/S, the infectious diseases company and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, US, have entered a collaboration whereby ACE BioSciences will support characterization of second-generation BCG-based tuberculosis (TB) vaccines under development by Aeras.

GlaxoSmithKline Biologicals and Aeras Global TB Vaccine Foundation Partner to Develop New TB Vaccine

October 19, 2005 - GlaxoSmithKline Biologicals (GSK Biologicals) and the Aeras Global TB Vaccine Foundation (Aeras) today announced a new public-private partnership to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A, which has shown promising results in preclinical studies. In addition, the vaccine has shown a good safety and immunogenicity profile in early-stage clinical trials conducted by GSK Biologicals. TB causes 2 million deaths a year, and is a leading cause of death amongst people with AIDS in the developing world.

Intercell AG and Statens Serum Institut Join Forces with Aeras for Novel Tuberculosis Vaccine

June 26, 2005 - Intercell AG and Statens Serum Institut (SSI) announced today that their joint project for the development of a new prophylactic tuberculosis vaccine has gained the support of the Aeras Global TB Vaccine Foundation. Aeras, an organization funded by the Bill and Melinda Gates Foundation, specializes in the development of novel TB vaccines with the aim of controlling the disease in developing countries.